1. Adelaide Research & Scholarship

Search


Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-10 of 14 (Search time: 0.002 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2010Association of early molecular response to nilotinib with probability of cytogenetic response in chronic myeloid leukemia patients (pts) who fail imatinibBranford, S.; Martinelli, G.; Saglio, G.; Kim, D.; Shou, Y.; Reynolds, J.; Woodman, R.; Kantarjian, H.; Hochhaus, A.; Radich, J.; American Society of Clinical Oncology Annual Meeting (2010 : Chicago, Ill.)
2010Mutation analysis of BCR-ABL tyrosine kinase domain in new chronic phase-chronic myeloid leukemia patients with suboptimal response or treatment failure from imatinib treatmentKim, D.; Kim, D.; Kim, S.; Goh, H.; Pane, F.; Hughes, T.; Radich, J.; Lin, P.; Saglio, G.; Branford, S.; Martinelli, G.; Soverini, S.; Hochhaus, A.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2013Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemiaStein, A.; Martinelli, G.; Hughes, T.; Muller, M.; Beppu, L.; Gottardi, E.; Branford, S.; Soverini, S.; Woodman, R.; Hochhaus, A.; Kim, D.; Saglio, G.; Radich, J.
2009Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaHochhaus, A.; O'Brien, S.; Guilhot, F.; Druker, B.; Branford, S.; Foroni, L.; Goldman, J.; Muller, M.; Radich, J.; Rudoltz, M.; Mone, M.; Gathmann, I.; Hughes, T.; Larson, R.
2009Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive valueHochhaus, A.; Muller, M.; Radich, J.; Branford, S.; Kantarjian, H.; Hanfstein, B.; Rousselot, P.; Kim, D.; Lipton, J.; Bleickhardt, E.; Lambert, A.; Hughes, T.
2006Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemiaBranford, S.; Cross, N.; Hochhaus, A.; Radich, J.; Saglio, G.; Kaeda, J.; Goldman, J.; Hughes, T.
2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
2009Harmonization of molecular monitoring of CML therapy in EuropeMuller, M.; Cross, N.; Erben, P.; Schenk, T.; Hanfstein, B.; Ernst, T.; Hehlmann, R.; Branford, S.; Saglio, G.; Hochhaus, A.
2010Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Hughes, T.; Hochhaus, A.; Branford, S.; Muller, M.; Kaeda, J.; Foroni, L.; Druker, B.; Guilhot, F.; Larson, R.; O'Brien, S.; Rudoltz, M.; Mone, M.; Wehrle, E.; Modur, V.; Goldman, J.; Radich, J.
2009Impact of baseline BCR-ABL mutations on response to Nilotinib in patients with chronic myeloid leukemia in chronic phaseHughes, T.; Saglio, G.; Branford, S.; Soverini, S.; Kim, J.; Muller, M.; Martinelli, G.; Cortes, J.; Beppu, L.; Gottardi, E.; Dongho, K.; Erben, P.; Shou, Y.; Haque, A.; Gallagher, N.; Radich, J.; Hochhaus, A.

Discover